Form 15-12G Nascent Pharma Holdings,

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 000-56703

 

Nascent pharma holdings, inc.

(Exact name of registrant as specified in its charter)

 

960 South Broadway, Suite 118
Hicksville, New York 11801

(516) 595-9544

(Address, including zip code, and telephone number, including area code, of

registrant’s principal executive offices)

 

Common Stock, no par value

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports

under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

	Rule 12g-4(a)(1)	☒
	Rule 12g-4(a)(2)	☐
	Rule 12h-3(b)(1)(i)	☐
	Rule 12h-3(b)(1)(ii)	☐
	Rule 15d-6	☐

 

Approximate number of holders of record as of the certification or notice date: 257

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

 

 

Date:	July 17, 2025
By:	/s/ Marco Alfonsi
	Marco Alfonsi
	Chief Executive Officer

.

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AIFA Outlines AI Application Strategy and Product Progress at First Annual Conference in Las Vegas
• Empowering "Mom, and More": Momcozy is Supplying the Best Solutions This Prime Day
• AMZsimple Targets Multi-Channel Scale With Dual-Marketplace Platform